I am excited to share that I was interviewed by Ana B. Nieto from El Pais! Thanks for a great article: "The two Latinos who were working with #artificialintelligence and #RNA long before everyone was talking about it," showcases Envisagenics journey highlighting our pioneering work in #AIDD and #RNAsplicing that ahappens to be a #femaleled and #minority led company in #NYC. Como #Latina y Colombiana me orgullese haber sido entrevistada por Ana del periodico #ElPais! Muchas gracias por mostrar nuestra ciencia y nuestra historia. Martin Akerman, mi equipo y yo nos alegramos de poder seguir adelantando nuestra vision de usar inteligencia artificial y ARN para desarollar curas contra enfermedades! To learn more about our story and to read the full article, check out the post below!"
Envisagenics is a proud female and minority-led company, so we are thrilled to have our journey recognized in a recent El Pais article by Ana B. Nieto titled, "The two Latinos who were working with artificial intelligence and RNA long before everyone was talking about it." Before AI and RNA became industry buzzwords, our co-founders, Maria Luisa Pineda, PhD. and Martin Akerman, pioneered SpliceCore®, our platform that leverages AI to identify novel RNA therapeutics targets and develops targeted treatments for cancer and other diseases. This year, we marked our tenth anniversary with a celebration at Cold Spring Harbor Laboratory and are looking forward to the continued development of our pipeline with our recent Series B. Read the full article here: bit.ly/46Dir4H #Envisagenics #Oncology #Biotech #ArtificialIntelligence
